Oramed Completes Patient Enrollment of its Pivotal Phase 3 Oral Insulin Study
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, has completed patient enrollment for its Phase 3 ORA-D-013-1 study…
Continue Reading
Oramed Completes Patient Enrollment of its Pivotal Phase 3 Oral Insulin Study